Drugs / ADX415
last change Dec 2008 re-read 3 minutes ago

ADX415

Developed for
essential hypertension
Investigated by
Addrenex Pharmaceuticals, Inc.

Trials 1

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00779181 Oct → Dec 2008 essential hypertension Addrenex Pharmaceuticals, Inc. Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ADX415 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00779181 ↗